General MedicationsINJECTIONGeneric
ETOPOSIDE
ETOPOSIDE
Standard Dose
20MG/ML
Max Dose
Refer to approved labeling
Primary Use
Marketing status: Discontinued
Summary
Approval overview ETOPOSIDE is listed in Drugs@FDA under application 204927 (ANDA).
Marketing status: Discontinued Active ingredient ETOPOSIDE Form and strength INJECTABLE;INJECTION - 20MG/ML Sponsor NATCO PHARMA USA Submission history Latest submission status date: 2017-10-31 00:00:00.
Structured Monograph
Clinical summary
Approval overview ETOPOSIDE is listed in Drugs@FDA under application 204927 (ANDA). Marketing status: Discontinued Active ingredient ETOPOSIDE Form and strength INJECTABLE;INJECTION - 20MG/ML Sponsor NATCO PHARMA USA Submission history Latest submission status date: 2017-10-31 00:00:00. Submission type: ORIG.
Monitoring
- • Review priority: STANDARD
- • Marketing status: Discontinued
Interaction Notes
- No interaction notes stored yet.